Palvella Therapeutics Q4 Earnings Report Released, Shares Up 11%
Shares of Palvella Therapeutics are moving higher after the company this morning reported its Q4 results and provided a corporate update. The company's 2025 earnings per share is ($3.71), compared to ($7.83) in 2024 and the consensus estimate of ($3.52). Palvella's pro forma cash was $274M as of December 31, 2025. In March, the company submitted a pre-new drug application meeting request to the FDA, with a meeting anticipated in Q2. The company said it expanded the development of Qtorin rapamycin into "clinically significant" angiokeratomas. Shares of Palvella Therapeutics are up 11%, or $12.70, to $123.37 in morning trading.
